Cytiva

BCRF is proud to partner with Cytiva to advance critical research. In association with Breast Cancer Awareness Month, Cytiva donates $1 to BCRF for every pack of Cytiva lab consumables products purchased. While this program originally started within their US and Canada divisions, each year they have expanded their footprint, adding campaigns in Europe, China, Australia, and New Zealand. With a dedicated employee engagement strategy, they are committed to being the end of breast cancer.

Additionally, Cytiva’s global employees show their support for BCRF through fundraising and engagement programs. The company works with sister brands across their Danaher parent company to amplify their fundraising efforts and fuel innovative BCRF research focused on metastatic disease.

At Cytiva, our mission is to advance and accelerate the development of therapeutics. With nearly 16 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers.  Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma, and contract manufacturers. Learn more at cytiva.com.

Cytiva generously supports the Evelyn H. Lauder Founder’s Fund for Metastatic Breast Cancer Research. The Founder’s Fund is the largest global study focused on metastatic breast cancer (MBC), which is the cause of nearly all deaths from breast cancer. The unparalleled scale and scope of this study will help to identify key differences between metastatic and primary tumors, ultimately revealing potential therapeutic targets for MBC. The Founder’s Fund leverages the power of technology, innovation, and collaboration to address this important consequence of breast cancer. In the U.S., one in eight women will develop breast cancer in her lifetime and, for 25–30 percent of these individuals, their cancer will spread or metastasize. Approximately 168,000 American women and men are living with MBC, and about 44,000 people will die from the disease this year. Metastatic breast cancer research is the only way we will end deaths from breast cancer.

Cytiva has been at the forefront of optimizing fundamental biological research to develop innovative solutions that improve patient outcomes. Since 2017, BCRF has been proud to partner with Cytiva, and together we are committed to funding research that saves lives by preventing and treating the most dangerous form of breast cancer.